Literature DB >> 4705152

Physiologic disposition of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (Me CCNU) in man.

R W Sponzo, V T DeVita, V T Oliverio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4705152     DOI: 10.1002/1097-0142(197305)31:5<1154::aid-cncr2820310517>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  7 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas.

Authors:  P Kari; W R McConnell; J M Finkel; D L Hill
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.

Authors:  Luning Zhuang; Jing Gao; Yong Zeng; Fei Yu; Bingjie Zhang; Mu Li; Hartmut Derendorf; Changxiao Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-03-05       Impact factor: 2.441

4.  Clinical pharmacokinetics of oral CCNU (lomustine).

Authors:  F Y Lee; P Workman; J T Roberts; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  The lethal activity and repair inhibition capacity of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (NSC 95466, PCNU), a nitrosourea with low carbamoylating activity.

Authors:  B Drewinko; L Y Yang
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 6.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

7.  In vitro chemosensitivity tests on xenografted human melanomas.

Authors:  A E Bateman; P J Selby; G G Steel; G D Towse
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.